Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on ...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, were $5 million (excluding any proceeds that may be received upon the ...

David Young, the President of Research & Development at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has increased his ...

Processa Pharmaceuticals Inc. (PCSA) stock has tumbled to a 52-week low, touching down at $0.65, with InvestingPro data ...

Processa Pharmaceuticals (PCSA) announced the pricing of its “reasonable best efforts” public offering with participation from the Company’s ...

Processa Pharmaceuticals, Inc. has successfully completed a public offering, raising $5 million to support its development of next-generation chemotherapeutic drugs aimed at improving efficacy and ...

根据 InvestingPro 的数据，Processa Pharmaceuticals, Inc. (NASDAQ: PCSA )的首席执行官George ...

Processa Pharmaceuticals, Inc. announced the pricing of a public offering aimed at raising approximately $5 million, with participation from its CEO, board members, and institutional investors.

Pre-Market: 8:38:07 a.m. EST ...